# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
TD Cowen analyst Joseph Thome initiates coverage on Alkermes (NASDAQ:ALKS) with a Buy rating and announces Price Target of $34.
HC Wainwright & Co. analyst Douglas Tsao reiterates Alkermes (NASDAQ:ALKS) with a Neutral and maintains $35 price target.
Alkermes plc (NASDAQ:ALKS) today announced new data from the full narcolepsy type 1 (NT1) cohort of a phase 1b, proof-of-conce...
Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024 PRNewswire – Late-Breaking Abstracts Containing Data From t...
Cantor Fitzgerald analyst Charles Duncan maintains Alkermes (NASDAQ:ALKS) with a Overweight and raises the price target from...
HC Wainwright & Co. analyst Douglas Tsao reiterates Alkermes (NASDAQ:ALKS) with a Neutral and maintains $35 price target.